5/8
08:41 pm
capr
A Look At Capricor Therapeutics (CAPR) Valuation After Phase 3 HOPE-3 Duchenne Data And FDA Review Progress [Yahoo! Finance]
Neutral
Report
A Look At Capricor Therapeutics (CAPR) Valuation After Phase 3 HOPE-3 Duchenne Data And FDA Review Progress [Yahoo! Finance]
5/4
04:05 pm
capr
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Low
Report
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
4/22
09:00 am
capr
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
Low
Report
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
4/16
04:05 pm
capr
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x [Seeking Alpha]
Low
Report
Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x [Seeking Alpha]
3/14
08:12 pm
capr
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]
3/13
04:16 pm
capr
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]
Low
Report
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]
3/13
02:07 pm
capr
Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.
Low
Report
Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.
3/13
12:38 pm
capr
Capricor Therapeutics (CAPR) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.
Low
Report
Capricor Therapeutics (CAPR) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.
3/13
09:29 am
capr
Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]
Medium
Report
Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]
3/12
11:35 pm
capr
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... [Yahoo! Finance]
3/12
08:04 pm
capr
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone [Seeking Alpha]
Medium
Report
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone [Seeking Alpha]
3/12
08:03 pm
capr
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/12
04:03 pm
capr
Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M [Seeking Alpha]
Medium
Report
Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M [Seeking Alpha]
3/12
04:01 pm
capr
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/12
09:32 am
capr
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy [Yahoo! Finance]
3/12
09:00 am
capr
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Low
Report
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
3/10
11:02 am
capr
Capricor Therapeutics (CAPR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Capricor Therapeutics (CAPR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
3/10
10:15 am
capr
Capricor extends rally as FDA to review rejected cell therapy [Seeking Alpha]
Medium
Report
Capricor extends rally as FDA to review rejected cell therapy [Seeking Alpha]
3/10
09:52 am
capr
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA [Yahoo! Finance]
3/10
09:25 am
capr
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Medium
Report
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
3/9
08:51 am
capr
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 [Yahoo! Finance]
Low
Report
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 [Yahoo! Finance]
3/9
08:30 am
capr
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
Low
Report
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
2/24
09:00 am
capr
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
Low
Report
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference